- Home
- RLAY vs DRRX Comparison
RLAY vs DRRX Comparison
Compare RLAY & DRRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RLAY
- DRRX
- Stock Information
- Founded
- RLAY 2015
- DRRX 1998
- Country
- RLAY United States
- DRRX United States
- Employees
- RLAY N/A
- DRRX N/A
- Industry
- RLAY Biotechnology: Biological Products (No Diagnostic Substances)
- DRRX Biotechnology: Pharmaceutical Preparations
- Sector
- RLAY Health Care
- DRRX Health Care
- Exchange
- RLAY Nasdaq
- DRRX Nasdaq
- Market Cap
- RLAY 619.0M
- DRRX 59.3M
- IPO Year
- RLAY 2020
- DRRX 2000
- Fundamental
- Price
- RLAY $3.99
- DRRX $1.91
- Analyst Decision
- RLAY Strong Buy
- DRRX Hold
- Analyst Count
- RLAY 13
- DRRX 1
- Target Price
- RLAY $18.00
- DRRX N/A
- AVG Volume (30 Days)
- RLAY 1.2M
- DRRX 699.4K
- Earning Date
- RLAY 11-05-2025
- DRRX 11-12-2025
- Dividend Yield
- RLAY N/A
- DRRX N/A
- EPS Growth
- RLAY N/A
- DRRX N/A
- EPS
- RLAY N/A
- DRRX N/A
- Revenue
- RLAY $8,355,000.00
- DRRX $1,657,000.00
- Revenue This Year
- RLAY $31.55
- DRRX N/A
- Revenue Next Year
- RLAY N/A
- DRRX $673.00
- P/E Ratio
- RLAY N/A
- DRRX N/A
- Revenue Growth
- RLAY N/A
- DRRX N/A
- 52 Week Low
- RLAY $1.78
- DRRX $0.48
- 52 Week High
- RLAY $8.32
- DRRX $2.64
- Technical
- Relative Strength Index (RSI)
- RLAY 58.70
- DRRX 67.35
- Support Level
- RLAY $3.87
- DRRX $1.86
- Resistance Level
- RLAY $4.20
- DRRX $1.97
- Average True Range (ATR)
- RLAY 0.21
- DRRX 0.03
- MACD
- RLAY 0.03
- DRRX -0.04
- Stochastic Oscillator
- RLAY 66.87
- DRRX 14.29
About RLAY Relay Therapeutics Inc.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies with the goal of bringing life-changing therapies to patients. the Dynamo platform integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-4008, RLY-2608, and GDC-1971 (formerly known as RLY-1971).
About DRRX DURECT Corporation
Durect Corp is a biopharmaceutical company. It is engaged in the research, development, and manufacturing of pharmaceutical products. The company develops pharmaceutical products based on two categories, which include new chemical entities and proprietary pharmaceutical programs. The company's pipeline products consist of DUR-928, POSIMIR, and others. Geographically, the company operates in the United States, Europe, Japan, and other countries, of which key revenue is derived from Europe.